Yuil Kim1, Mineui Hong1, In-Gu Do1, Sang Yun Ha1, Dakeun Lee2, Yeon-Lim Suh3. 1. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Department of Pathology, Ajou University School of Medicine, Suwon, Republic of Korea. 3. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: ylsuh76@skku.edu.
Abstract
BACKGROUND: Wnt5a, a non-canonical Wnt ligand, has been shown to play tumor-promoting or tumor-suppressive roles in different neoplasms. Increased Wnt5a expression and Wnt5a-dependent invasive activity that is mediated by one of its receptors, Ryk, have been reported in glioblastomas. METHODS: We investigated the protein expression of Wnt5a, its receptors Ryk and Ror2, and the canonical Wnt pathway marker β-catenin in 186 cases of glioblastoma and its variants. Associations with clinicopathological and molecular variables and prognosis were analyzed. RESULTS: All glioblastoma cases expressed Wnt5a, Ryk and Ror2 with a different grade. The expression of both Ryk and Ror2 correlated with that of Wnt5a in glioblastomas. The expression of β-catenin did not correlate with any of Wnt5a, Ryk or Ror2. Wnt5a expression was significantly different among subgroups of the glioblastoma. However, none of Wnt5a, Ryk or Ror2 had a prognostic impact on glioblastoma. For β-catenin, a shorter progression-free survival was noted in the glioblastoma with oligodendroglioma component (GBMO) subgroup. CONCLUSIONS: Our results corroborated previous findings of Ryk-mediated Wnt5a effect, and suggested a role for Ror2 in the Wnt5a machinery in glioblastoma.
BACKGROUND:Wnt5a, a non-canonical Wnt ligand, has been shown to play tumor-promoting or tumor-suppressive roles in different neoplasms. Increased Wnt5a expression and Wnt5a-dependent invasive activity that is mediated by one of its receptors, Ryk, have been reported in glioblastomas. METHODS: We investigated the protein expression of Wnt5a, its receptors Ryk and Ror2, and the canonical Wnt pathway marker β-catenin in 186 cases of glioblastoma and its variants. Associations with clinicopathological and molecular variables and prognosis were analyzed. RESULTS: All glioblastoma cases expressed Wnt5a, Ryk and Ror2 with a different grade. The expression of both Ryk and Ror2 correlated with that of Wnt5a in glioblastomas. The expression of β-catenin did not correlate with any of Wnt5a, Ryk or Ror2. Wnt5a expression was significantly different among subgroups of the glioblastoma. However, none of Wnt5a, Ryk or Ror2 had a prognostic impact on glioblastoma. For β-catenin, a shorter progression-free survival was noted in the glioblastoma with oligodendroglioma component (GBMO) subgroup. CONCLUSIONS: Our results corroborated previous findings of Ryk-mediated Wnt5a effect, and suggested a role for Ror2 in the Wnt5a machinery in glioblastoma.
Authors: Céline S Gonçalves; Ana Xavier-Magalhães; Eduarda P Martins; Afonso A Pinto; Manuel Melo Pires; Célia Pinheiro; Rui M Reis; Nuno Sousa; Bruno M Costa Journal: Mol Oncol Date: 2020-05-06 Impact factor: 6.603
Authors: Farida S Akhtari; Adrian J Green; George W Small; Tammy M Havener; John S House; Kyle R Roell; David M Reif; Howard L McLeod; Timothy Wiltshire; Alison A Motsinger-Reif Journal: PLoS Genet Date: 2021-08-26 Impact factor: 5.917
Authors: Stefanie Thiele; Ariane Zimmer; Andy Göbel; Tilman D Rachner; Sandra Rother; Susanne Fuessel; Michael Froehner; Manfred P Wirth; Michael H Muders; Gustavo B Baretton; Franz Jakob; Martina Rauner; Lorenz C Hofbauer Journal: Oncotarget Date: 2018-06-05